Literature DB >> 24380728

Ubiquitin-proteasome system and hereditary cardiomyopathies.

Saskia Schlossarek1, Norbert Frey2, Lucie Carrier3.   

Abstract

Adequate protein turnover is essential for cardiac homeostasis. Different protein quality controls are involved in the maintenance of protein homeostasis, including molecular chaperones and co-chaperones, the autophagy-lysosomal pathway, and the ubiquitin-proteasome system (UPS). In the last decade, a series of evidence has underlined a major function of the UPS in cardiac physiology and disease. Particularly, recent studies have shown that dysfunctional proteasomal function leads to cardiac disorders. Hypertrophic and dilated cardiomyopathies are the two most prevalent inherited cardiomyopathies. Both are primarily transmitted as an autosomal-dominant trait and mainly caused by mutations in genes encoding components of the cardiac sarcomere, including a relevant striated muscle-specific E3 ubiquitin ligase. A growing body of evidence indicates impairment of the UPS in inherited cardiomyopathies as determined by measurement of the level of ubiquitinated proteins, the activities of the proteasome and/or the use of fluorescent UPS reporter substrates. The present review will propose mechanisms of UPS impairment in inherited cardiomyopathies, summarize the potential consequences of UPS impairment, including activation of the unfolded protein response, and underline some therapeutic options available to restore proteasome function and therefore cardiac homeostasis and function. This article is part of a Special Issue entitled "Protein Quality Control, the Ubiquitin Proteasome System, and Autophagy".
Copyright © 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Dilated cardiomyopathy; Hypertrophic cardiomyopathy; Ubiquitin-proteasome system

Mesh:

Substances:

Year:  2013        PMID: 24380728     DOI: 10.1016/j.yjmcc.2013.12.016

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  33 in total

1.  Proteostasis in epicardial versus subcutaneous adipose tissue in heart failure subjects with and without diabetes.

Authors:  A Burgeiro; A C Fonseca; D Espinoza; L Carvalho; N Lourenço; M Antunes; E Carvalho
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-04-04       Impact factor: 5.187

2.  Effects of MYBPC3 loss-of-function mutations preceding hypertrophic cardiomyopathy.

Authors:  Adam S Helms; Vi T Tang; Thomas S O'Leary; Sabrina Friedline; Mick Wauchope; Akul Arora; Aaron H Wasserman; Eric D Smith; Lap Man Lee; Xiaoquan W Wen; Jordan A Shavit; Allen P Liu; Michael J Previs; Sharlene M Day
Journal:  JCI Insight       Date:  2020-01-30

3.  Cardiac Arrest Alters Regional Ubiquitin Levels in Association with the Blood-Brain Barrier Breakdown and Neuronal Damages in the Porcine Brain.

Authors:  Hari S Sharma; Ranjana Patnaik; Aruna Sharma; José Vicente Lafuente; Adriana Miclescu; Lars Wiklund
Journal:  Mol Neurobiol       Date:  2015-06-25       Impact factor: 5.590

4.  Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.

Authors:  Constantine S Mitsiades
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

Review 5.  Cardiac microtubules in health and heart disease.

Authors:  Matthew A Caporizzo; Christina Yingxian Chen; Benjamin L Prosser
Journal:  Exp Biol Med (Maywood)       Date:  2019-08-09

Review 6.  Research priorities in sarcomeric cardiomyopathies.

Authors:  Jolanda van der Velden; Carolyn Y Ho; Jil C Tardiff; Iacopo Olivotto; Bjorn C Knollmann; Lucie Carrier
Journal:  Cardiovasc Res       Date:  2015-01-28       Impact factor: 10.787

7.  Hydrogen sulfide regulates muscle RING finger-1 protein S-sulfhydration at Cys44 to prevent cardiac structural damage in diabetic cardiomyopathy.

Authors:  Xiaojiao Sun; Dechao Zhao; Fangping Lu; Shuo Peng; Miao Yu; Ning Liu; Yu Sun; Haining Du; Bingzhu Wang; Jian Chen; Shiyun Dong; Fanghao Lu; Weihua Zhang
Journal:  Br J Pharmacol       Date:  2019-04-29       Impact factor: 8.739

8.  Vps34 regulates myofibril proteostasis to prevent hypertrophic cardiomyopathy.

Authors:  Hirotaka Kimura; Satoshi Eguchi; Junko Sasaki; Keiji Kuba; Hiroki Nakanishi; Shunsuke Takasuga; Masakazu Yamazaki; Akiteru Goto; Hiroyuki Watanabe; Hiroshi Itoh; Yumiko Imai; Akira Suzuki; Noboru Mizushima; Takehiko Sasaki
Journal:  JCI Insight       Date:  2017-01-12

9.  Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3-knock-in mice.

Authors:  Frederik Flenner; Birgit Geertz; Silke Reischmann-Düsener; Florian Weinberger; Thomas Eschenhagen; Lucie Carrier; Felix W Friedrich
Journal:  J Physiol       Date:  2017-02-07       Impact factor: 5.182

10.  Altered C10 domain in cardiac myosin binding protein-C results in hypertrophic cardiomyopathy.

Authors:  Diederik W D Kuster; Thomas L Lynch; David Y Barefield; Mayandi Sivaguru; Gina Kuffel; Michael J Zilliox; Kyoung Hwan Lee; Roger Craig; Rajasekaran Namakkal-Soorappan; Sakthivel Sadayappan
Journal:  Cardiovasc Res       Date:  2019-12-01       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.